10561214

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:45:56 ON 17 NOV 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 20:46:01 ON 17 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 NOV 2008  HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES:  16 NOV 2008  HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561214.str
```



chain nodes :
13 14 15 16 17 18 19 26 27 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 20 21 22 23 24 25
chain bonds :
1-13 8-19 9-20 13-14 13-26 14-15 14-16 15-18 16-17 21-27 22-32 23-28
24-30 25-31 28-29
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 5-10 6-12 7-8 8-9 10-11 11-12 20-21
20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-6 1-13 2-3 2-7 3-4 3-9 4-5 5-6 5-10 6-12 7-8 8-9 10-11 11-12
13-14 23-28
exact bonds :
8-19 9-20 13-26 14-15 14-16 15-18 16-17 21-27 22-32 24-30 25-31 28-29
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 20:46:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 452 TO 1228
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 20:46:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 839 TO ITERATE

100.0% PROCESSED 839 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> fil capl
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 20:46:29 ON 17 NOV 2008

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21

FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4   3 L3

=> d l4 ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:588981 CAPLUS
DOCUMENT NUMBER: 143:115565
TITLE: Preparation of tricyclic heterocyclic compound as CRF antagonist
INVENTOR(S): Nunoya, Kenichi; Matsumura, Naoya; Sugioka, Makiko; Moriguchi, Hideki; Katsumata, Seishi
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061508	A1	20050707	WO 2004-JP19658	20041221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2003-425778 A 20031222
OTHER SOURCE(S): MARPAT 143:115565
GI



I



II

AB Title compds. represented by the formula I [wherein R1, R2 = independently (protected) OH; R3, R = independently (protected) OH or oxo; R4 = R-substituted Et2CH; R5 = (un)oxidized Me; m, n = independently 0-3; and pharmaceutically acceptable salts, solvates, N-oxides, and pro-drugs thereof] were prepared as CRF antagonist. For example, II was given in a

3-step synthesis starting from 4-(2-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazole-5-amine. I were tested for binding activity and antagonistic activity of human CRF 1 with IC50 value of less than 1μM, resp. Thus, I and their pharmaceutical compns. are useful as CRF antagonist for the prevention and/or treatment of psychoneurotic diseases or digestive diseases (no data).

IT 441060-02-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclopenta[d]pyrazolo[1,5-a]pyrimidine derivs. as CRF 1 antagonist)

RN 441060-02-2 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154717 CAPLUS
DOCUMENT NUMBER: 142:93846
TITLE: Preparation of pyrazolopyrimidine derivatives as CRF antagonists
INVENTOR(S): Hasegawa, Tomoyuki; Matsui, Toshiaki; Araki, Hiroshi; Saito, Tetsuji; Obitsu, Tetsuo; Okamoto, Masaki; Gemba, Yuichi; Mikami, Yutaka
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113344	A1	20041229	WO 2004-JP9263	20040624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249629	A1	20041229	AU 2004-249629	20040624
CA 2529561	A1	20041229	CA 2004-2529561	20040624
EP 1637531	A1	20060322	EP 2004-746732	20040624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011923	A	20060815	BR 2004-11923	20040624
CN 1842530	A	20061004	CN 2004-80024365	20040624
MX 2005PA13917	A	20060309	MX 2005-PA13917	20051219
NO 2005006093	A	20060324	NO 2005-6093	20051221
IN 2005CN03513	A	20070831	IN 2005-CN3513	20051223
PRIORITY APPLN. INFO.:			JP 2003-181908 A	20030625
			WO 2004-JP9263 W	20040624

OTHER SOURCE(S): MARPAT 142:93846
GI



I

AB The title compds., such as 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxy-phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]-pyrimidine methanesulfonic acid salt (I•MeSO3H), are prepared as corticotropin-releasing factor (CRF) receptor antagonists. I•MeSO3H showed antagonistic activity with IC50 of <1 μM against human CRF receptor. Formulations containing I•MeSO3H as an active ingredient were also described.

IT 817636-92-3P 817636-93-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazolopyrimidine derivs. as CRF antagonists)

RN 817636-92-3 CAPLUS

CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 441060-02-2
CMF C22 H27 Cl N4 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 817636-93-4 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 441060-02-2
CMF C22 H27 Cl N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT 441060-02-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyrimidine derivs. as CRF antagonists)
RN 441060-02-2 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:521741 CAPLUS
DOCUMENT NUMBER: 137:93768
TITLE: Preparation of tricyclic heterocyclic derivative compounds as antagonists of corticotropin release factor receptor and drugs containing these compounds as the active ingredient
INVENTOR(S): Nakai, Hisao; Kagamiishi, Yoshifumi
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 456 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053565	A1	20020711	WO 2001-JP11581	20011227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432148	A1	20020711	CA 2001-2432148	20011227
AU 2002226674	A1	20020716	AU 2002-226674	20011227
AU 2002226674	B2	20070322		
EP 1354884	A1	20031022	EP 2001-995808	20011227
EP 1354884	B1	20071010		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003653	A2	20040301	HU 2003-3653	20011227
HU 2003003653	A3	20060529		
CN 1491225	A	20040421	CN 2001-822720	20011227
CN 1274690	C	20060913		
JP 3528968	B2	20040524	JP 2002-555088	20011227
BR 2001016609	A	20050215	BR 2001-16609	20011227
NZ 526712	A	20050324	NZ 2001-526712	20011227
CN 1896076	A	20070117	CN 2006-10106154	20011227
RU 2291869	C2	20070120	RU 2003-119138	20011227
EP 1832590	A2	20070912	EP 2007-111569	20011227
EP 1832590	A3	20071114		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
AT 375345	T	20071015	AT 2001-995808	20011227
ES 2294047	T3	20080401	ES 2001-995808	20011227
NO 2003002956	A	20030828	NO 2003-2956	20030626
ZA 2003005003	A	20050527	ZA 2003-5003	20030626
MX 2003PA05913	A	20050419	MX 2003-PA5913	20030627
KR 843281	B1	20080709	KR 2003-708815	20030627
US 20040072833	A1	20040415	US 2003-250328	20030630
US 7034153	B2	20060425		
JP 2004083597	A	20040318	JP 2003-406938	20031205

US 20060122392 A1 20060608 US 2005-219736 20050907
PRIORITY APPLN. INFO.: JP 2000-402517 A 20001228
CN 2001-822720 A3 20011227
EP 2001-995808 A3 20011227
JP 2002-555088 A3 20011227
WO 2001-JP11581 W 20011227
US 2003-250328 A1 20030630
OTHER SOURCE(S): MARPAT 137:93768
GI



I

AB Tricyclic heterocyclic derivs. such as 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, 5,7-dihydrofuro[3,4-d]pyrazolo[1,5-a]pyrimidine, and 6,7-dihydro-5H-cyclopenta[e]pyrrolo[2,3-b]pyridine derivs. represented by the following general formula (I) and pharmaceutically acceptable salts thereof [wherein X, Y = C or N, provided that both X and Y are not simultaneously N; W = C, N; U, Z = (un)substituted CH or NH, N, O, S, CO, C(:S); ring A = optionally substituted C4-6 carbocyclic ring or 4 to 5-membered heterocyclic ring possessing at least one of N, O, and S atom; R1 = (un)substituted C1-8 alkyl, C2-8 alkynyl, C2-8 alkenyl, NH2, or OH, SH, S(O)nR7, etc. (wherein n = 0-2; R7 = C1-8 alkyl, optionally substituted C3-10 bicyclic carbocyclyl, 3- to 10-membered ring bicyclic heterocyclyl, mono or bicyclic heterocyclyl-C1-4 alkyl, mono or bicyclic heterocyclyl-C1-4 alkyl, etc.); R3 = 5 to 10-membered mono or bicyclic heterocyclyl containing 1-4 N, 1 or 2 O and/or 1 or 2 O S atoms substituted by 1-5 groups selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, halo, etc.] or pharmacol. acceptable salts thereof or hydrates thereof are prepared Because of having a corticotropin release factor (CRF) receptor antagonism, the compds. I are useful in preventing and/or treating diseases caused by unusual secretion of corticotropin release factor, including depression (single episode, recurrent, post-delivery, or child abuse-induced depression), anxiety, anxiety disorders (panic disorder, specific phobia, acrophobia, social phobia, or obsessive-compulsive disorder), emotional disorder, dipolar disorder, post-traumatic stress, digestive ulcer, diarrhea, constipation, irritable bowel syndrome, inflammatory bowel diseases (ulcerous colitis or Crohn's disease), gastrointestinal function disorder accompanied by stress, neurol. vomiting, eating disorder [neurol. anorexia (anorexia nervosa) or overeating], obesity, stress-induced sleep disorder, fibromuscular pain-induced sleep disorder, stress-induced immunosuppression, stress-induced headache, stress-induced fever, stress-induced pain, operation invasion stress, chronic articular rheumatism, osteoarthritis, osteoporosis, psoriasis, and thyroid gland malfunction syndrome. The above diseases also include uveitis, asthma, diseases based on inappropriate antidiarrheic hormone, pain, inflammation, allergy, head trauma, spinal cord injury, ischemic neuron damage, Cushing's disease,

seizure (attack), spasm, muscle spasm, epileptic ischemia, Parkinson's disease, Huntington's disease, urinary incontinence, Alzheimer's disease, Alzheimer-type senile dementia, multi-infarction dementia, amyotrophic lateral sclerosis, hypoglycemia, cardiovascular or cardiac diseases (hypertension, tachycardia, or ischemic heart failure), and alc. or drug withdrawal. Thus, a mixture of 150 mg 8-chloro-2-methyl-3-(2-methyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and 0.60 mL 3-pentylamine was heated at 140° for 1 h to give 8-(3-pentylamino)-2-methyl-3-(2-methyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine (II). The compds. I inhibited the binding of 125I-CRF to human CRF receptor with IC50 of <1 μM. A tablet and an ampule formulation containing II were prepared

IT 441057-63-2P 441060-02-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic heterocyclic derivative compds. as antagonists of corticotropin release factor receptor and drugs containing them as active ingredient)

RN 441057-63-2 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 441060-02-2 CAPLUS
CN 5H-Cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10561214

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.83	195.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

STN INTERNATIONAL LOGOFF AT 20:46:56 ON 17 NOV 2008